[Drugs for Amyotrophic Lateral Sclerosis]

Area of Science:

• Neurology
• Pharmacology

Context:

• Insurance coverage in Japan for riluzole and edaravone in amyotrophic lateral sclerosis (ALS) treatment.
• Both drugs demonstrate potential in prolonging survival and inhibiting ALS progression.
• Clinical trial data may not universally apply to all ALS patients.

Purpose:

• To review the current status of riluzole and edaravone for ALS treatment in Japan.
• To highlight the availability of oral edaravone and symptomatic treatments like morphine.
• To emphasize the importance of individualized risk-benefit assessments for ALS therapies.

Summary:

• Riluzole and edaravone are insurance-covered ALS treatments in Japan, offering survival and progression benefits.
• Realizing treatment effects can be challenging, and clinical trial applicability varies among patients.
• An oral edaravone formulation launched in April 2023, with morphine options for symptom management.

Impact:

• Informs clinicians and patients about available ALS treatment options and their limitations in Japan.
• Underscores the need for careful consideration of individual patient factors when prescribing riluzole and edaravone.
• Highlights advancements in ALS pharmacotherapy, including new formulations and symptomatic relief options.